Developer of novel, proprietary products and technologies for blood supply selects clinivation Global xi to manage its medical products approvals and submissions.
Natick, MA, March 13, 2008 – clinivation, Inc. announced today that Cerus Corporation (NASDAQ: CERS) has selected the clinivation Global Enterprise Solution for Market Clearance Management Market Clearance Management solution. “Cerus is an emerging leader in next-generation technologies to improve the safety of blood transfusions,” said Joseph Kozikowski, M.D., clinivation’s Chief Executive Officer. “We are pleased that Cerus’ senior management has selected Global xi to help impact their market clearance operations to better achieve their sales and marketing objectives,” he continued. Clinivation Global xi software enables medical device companies to sell more products to more countries faster and easier than ever before. Clinivation Global xi is the first complete solution targeted at automating the business processes for market clearance operations worldwide.
About Cerus Corporation
Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion. Cerus currently markets the INTERCEPT Blood System for both platelets and plasma in Europe and the Middle East. The Company is also pursuing regulatory approvals in the United States and other countries. The INTERCEPT red blood cell system is currently in clinical development.
For more information, please visit www.cerus.com.
